Search This Blog

Thursday, November 5, 2026

Lexicon STENO1 safety data for Q1 2027 ZYNQUISTA resubmission meets requirements

 

Lexicon Pharmaceuticals posts Q3 net loss of $14M on $11.3M revenue and reports STENO1 safety data for Q1 2027 ZYNQUISTA resubmission

  • Lexicon's Q3 net loss translated to $0.03 per share overall.
  • Q3 2026 revenue was $11.2M, down 21% YoY, beating revenue estimates.
  • STENO1 safety data met FDA-agreed requirements to support Q1 2027 ZYNQUISTA NDA resubmission in type 1 diabetes.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)